Accelerate Diagnostics Inc. (NASDAQ:AXDX) – William Blair raised their FY2016 earnings per share estimates for Accelerate Diagnostics in a report issued on Thursday. William Blair analyst B. Weinstein now anticipates that the firm will earn ($1.33) per share for the year, up from their previous forecast of ($1.37). William Blair also issued estimates for Accelerate Diagnostics’ Q4 2016 earnings at ($0.35) EPS, Q1 2017 earnings at ($0.34) EPS, Q2 2017 earnings at ($0.34) EPS, Q3 2017 earnings at ($0.31) EPS, Q4 2017 earnings at ($0.30) EPS and FY2017 earnings at ($1.29) EPS.

AXDX has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 27th. BTIG Research raised shares of Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a research note on Thursday, August 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Tuesday, August 9th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $26.25.

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Shares of Accelerate Diagnostics (NASDAQ:AXDX) opened at 26.25 on Monday. The company’s 50-day moving average is $24.42 and its 200-day moving average is $19.76. The stock’s market cap is $1.35 billion. Accelerate Diagnostics has a 52-week low of $10.29 and a 52-week high of $28.50.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Group LTD boosted its position in shares of Accelerate Diagnostics by 3.7% in the third quarter. BlackRock Group LTD now owns 11,292 shares of the company’s stock worth $308,000 after buying an additional 405 shares during the period. California State Teachers Retirement System boosted its position in shares of Accelerate Diagnostics by 1.0% in the third quarter. California State Teachers Retirement System now owns 48,811 shares of the company’s stock worth $1,331,000 after buying an additional 500 shares during the period. Rhumbline Advisers boosted its position in shares of Accelerate Diagnostics by 2.3% in the third quarter. Rhumbline Advisers now owns 24,352 shares of the company’s stock worth $664,000 after buying an additional 537 shares during the period. American International Group Inc. boosted its position in shares of Accelerate Diagnostics by 5.3% in the second quarter. American International Group Inc. now owns 13,263 shares of the company’s stock worth $191,000 after buying an additional 663 shares during the period. Finally, Geneva Advisors LLC boosted its position in shares of Accelerate Diagnostics by 3.6% in the second quarter. Geneva Advisors LLC now owns 27,180 shares of the company’s stock worth $391,000 after buying an additional 934 shares during the period. Hedge funds and other institutional investors own 35.69% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

5 Day Chart for NASDAQ:AXDX

Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.